{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:51:23Z","timestamp":1791910283242,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004168","name":"Universit\u00e4t zu L\u00fcbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004168","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite some common pathogenic themes, the association of hidradenitis suppurativa (HS) and rheumatoid arthritis (RA) has been poorly investigated. We aimed to evaluate the bidirectional association between HS and RA. A population-based study was conducted to compare HS patients (<jats:italic>n<\/jats:italic>\u2009=\u20096779) with age-, sex- and ethnicity-matched control subjects (<jats:italic>n<\/jats:italic>\u2009=\u200933,260) with regard to the incidence of new-onset and the prevalence of preexisting RA. Adjusted hazard ratios (HRs) and adjusted odds ratios (ORs) were estimated. The prevalence of preexisting RA was greater among patients with HS relative to controls (0.5% vs 0.3%. respectively; <jats:italic>p<\/jats:italic>\u2009=\u20090.019). The odds of being diagnosed with HS were 1.6-fold higher in patients with a history of RA (fully-adjusted OR, 1.66; 95% CI, 1.11\u20132.49; <jats:italic>p<\/jats:italic>\u2009=\u20090.014). The incidence rate of new-onset RA was estimated at 4.3 (95% CI, 2.5\u20136.8) and 2.4 (95% CI, 1.8\u20133.2) cases per 10,000 person-years among patients with HS and controls, respectively. The risk of RA was comparable between patients with HS and controls (fully-adjusted HR, 1.45; 95% CI, 0.77\u20132.72; <jats:italic>p<\/jats:italic>\u2009=\u20090.249). Compared to other patients with HS, those with HS and comorbid RA were older, had a higher prevalence of diabetes mellitus, hypertension, and hyperlipidemia, and had a comparable risk of all-cause mortality. In conclusions, a preexisting diagnosis of RA predisposes individuals to develop HS. Clinicians managing patients with HS and RA should be aware of this association. Further research is required to delineate the underlying pathomechanism of this observation.<\/jats:p>","DOI":"10.1007\/s12026-021-09221-4","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T23:04:49Z","timestamp":1629327889000},"page":"533-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Hidradenitis suppurativa and rheumatoid arthritis: evaluating the bidirectional association"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9971-9151","authenticated-orcid":false,"given":"Khalaf","family":"Kridin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Shavit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon D","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"9221_CR1","doi-asserted-by":"crossref","unstructured":"Saunte DML, Jemec GBE. Hidradenitis suppurativa: Advances in diagnosis and treatment. JAMA - J Am Med Assoc. 2017. p. 2019\u201332.","DOI":"10.1001\/jama.2017.16691"},{"key":"9221_CR2","doi-asserted-by":"crossref","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol Mosby Inc.; 2020. 82: 1045\u201358.","DOI":"10.1016\/j.jaad.2019.08.090"},{"key":"9221_CR3","doi-asserted-by":"crossref","unstructured":"Jemec GBE, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem. J. Am. Acad. Dermatol. [Internet]. Mosby Inc.; 2015;73:S4\u20137.","DOI":"10.1016\/j.jaad.2015.07.052"},{"key":"9221_CR4","doi-asserted-by":"crossref","unstructured":"Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies. J. Am. Acad. Dermatol. [Internet]. J Am Acad Dermatol; 2008 [cited 2021 May 23];59:596\u2013601. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18674845\/.","DOI":"10.1016\/j.jaad.2008.06.020"},{"key":"9221_CR5","doi-asserted-by":"crossref","unstructured":"Nguyen T V., Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life [Internet]. J. Eur. Acad. Dermatology Venereol. Blackwell Publishing Ltd; 2021 [cited 2021 May 23]. p. 50\u201361. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32460374\/.","DOI":"10.1111\/jdv.16677"},{"key":"9221_CR6","doi-asserted-by":"crossref","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis [Internet]. Lancet. Lancet Publishing Group; 2016. p. 2023\u201338.","DOI":"10.1016\/S0140-6736(16)30173-8"},{"key":"9221_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jdcr.2019.12.016","volume":"6","author":"MS Alam","year":"2020","unstructured":"Alam MS, LaBelle B. Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis. JAAD Case Reports [Internet]. 2020;6:219\u201321.","journal-title":"JAAD Case Reports [Internet]."},{"key":"9221_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00282","author":"S Garcovich","year":"2019","unstructured":"Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019. https:\/\/doi.org\/10.3389\/fphar.2019.00282.","journal-title":"Front Pharmacol"},{"key":"9221_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00403-020-02040-x","volume":"312","author":"K Kridin","year":"2020","unstructured":"Kridin K, Jones VA, Patel PM, Gibson FT, Amber KT, Cohen AD. Hidradenitis suppurativa and pemphigus: a cross-sectional study. Arch Dermatol Res. 2020;312:501\u20135.","journal-title":"Arch Dermatol Res"},{"key":"9221_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/ced.14186","volume":"45","author":"K Kridin","year":"2020","unstructured":"Kridin K, Amber KT, Comaneshter D, Cohen AD. Amyloidosis in hidradenitis suppurativa: a cross-sectional study and review of the literature. Clin Exp Dermatol. 2020;45:565\u201371.","journal-title":"Clin Exp Dermatol"},{"key":"9221_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12026-020-09160-6","volume":"68","author":"K Kridin","year":"2020","unstructured":"Kridin K, Jones VA, Patel PM, Zelber-Sagi S, Hammers CM, Damiani G, et al. Patients with pemphigus are at an increased risk of developing rheumatoid arthritis: a large-scale cohort study. Immunol Res. 2020;68:373\u20138.","journal-title":"Immunol Res"},{"key":"9221_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10067-020-05253-7","volume":"40","author":"K Kridin","year":"2021","unstructured":"Kridin K, Damiani G, Cohen AD. Rheumatoid arthritis and pyoderma gangrenosum: a population-based case-control study. Clin Rheumatol. 2021;40:521\u20138.","journal-title":"Clin Rheumatol"},{"key":"9221_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"9221_CR14","first-page":"243","volume":"153","author":"V Lora","year":"2018","unstructured":"Lora V, Cerroni L, Cota C. Skin manifestations of rheumatoid arthritis. G Ital di Dermatologia e Venereol. 2018;153:243\u201355.","journal-title":"G. Ital. di Dermatologia e Venereol."},{"key":"9221_CR15","doi-asserted-by":"crossref","unstructured":"Sayah A, English JC. Rheumatoid arthritis: A review of the cutaneous manifestations. J. Am. Acad. Dermatol. 2005. p. 191\u2013209.","DOI":"10.1016\/j.jaad.2004.07.023"},{"key":"9221_CR16","first-page":"684","volume":"20","author":"IA Rosner","year":"1993","unstructured":"Rosner IA, Burg CG, Wisnieski JJ, Schacter BZ, Richter DE. The clinical spectrum of the arthropathy associated with hidradenitis suppurativa and acne conglobata. J Rheumatol. 1993;20:684\u20137.","journal-title":"J Rheumatol"},{"key":"9221_CR17","doi-asserted-by":"crossref","unstructured":"Shlyankevich J, Chen AJ, Kim GE, Kimball AB (2014) Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis. J Am Acad Dermatol Mosby Inc 71:1144\u201350.","DOI":"10.1016\/j.jaad.2014.09.012"},{"key":"9221_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3899\/jrheum.130977","volume":"41","author":"P Richette","year":"2014","unstructured":"Richette P, Molto A, Viguier M, Dawidowicz K, Hayem G, Nassif A, et al. Hidradenitis suppurativa associated with spondyloarthritis - Results from a multicenter national prospective study. J Rheumatol. 2014;41:490\u20134.","journal-title":"J Rheumatol"},{"key":"9221_CR19","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1111\/jdv.15071","volume":"32","author":"JH Lee","year":"2018","unstructured":"Lee JH, Kwon HS, Jung HM, Kim GM, Bae JM. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatology Venereol. 2018;32:1784\u201390.","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"9221_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/jamadermatol.2019.4590","volume":"156","author":"MC Schneeweiss","year":"2020","unstructured":"Schneeweiss MC, Kim SC, Schneeweiss S, Rosmarin D, Merola JF. Risk of inflammatory arthritis after a new diagnosis of hidradenitis suppurativa. JAMA Dermatol. 2020;156:342\u20135.","journal-title":"JAMA Dermatol"},{"key":"9221_CR21","doi-asserted-by":"crossref","unstructured":"Miller IM, McAndrew RJ, Hamzavi I. Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa. Dermatol. Clin. 2016. p. 7\u201316.","DOI":"10.1016\/j.det.2015.08.002"},{"key":"9221_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016;375:422\u201334.","journal-title":"N Engl J Med"},{"key":"9221_CR23","doi-asserted-by":"crossref","unstructured":"Scott DL, Ibrahim F, Farewell V, Go\u2019Keeffe A, Walker D, Kelly C, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ [Internet]. BMJ Publishing Group; 2015;350.","DOI":"10.1136\/bmj.h1046"},{"key":"9221_CR24","doi-asserted-by":"crossref","unstructured":"Grand D, Navrazhina K, Frew JW. Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa. Exp. Dermatol. [Internet]. Blackwell Publishing Ltd; 2020;29:86\u201392.","DOI":"10.1111\/exd.14056"},{"key":"9221_CR25","doi-asserted-by":"crossref","unstructured":"Kanni T, Zenker O, Habel M, Riedemann N, Giamarellos-Bourboulis EJ. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis? Br. J. Dermatol. [Internet]. Blackwell Publishing Ltd; 2018;179:413\u20139.","DOI":"10.1111\/bjd.16428"},{"key":"9221_CR26","doi-asserted-by":"crossref","unstructured":"Hashimoto M, Hirota K, Yoshitomi H, Maeda S, Teradaira S, Akizuki S, et al. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J. Exp. Med. [Internet]. J Exp Med; 2010;207:1135\u201343.","DOI":"10.1084\/jem.20092301"},{"key":"9221_CR27","doi-asserted-by":"crossref","unstructured":"Ingram JR. The epidemiology of hidradenitis suppurativa*. Br. J. Dermatol. [Internet]. Blackwell Publishing Ltd; 2020;183:990\u20138.","DOI":"10.1111\/bjd.19435"},{"key":"9221_CR28","unstructured":"Ishikawa Y, Terao C. The Impact of Cigarette Smoking on Risk of Rheumatoid Arthritis: A Narrative Review [Internet]. Cells. NLM (Medline); 2020 [cited 2021 May 22]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32092988\/."}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09221-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-021-09221-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09221-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T06:25:12Z","timestamp":1636525512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-021-09221-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9221"],"URL":"https:\/\/doi.org\/10.1007\/s12026-021-09221-4","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"assertion":[{"value":"5 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ADC served as an advisor, investigator, or speaker for Abbvie, BI, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer, and Rafa. None of the other authors have any conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}